Skip to content

Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.

Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02796040
Acronym
TCI-IRMdiff
Enrollment
75
Registered
2016-06-10
Start date
2016-02-29
Completion date
2017-08-31
Last updated
2016-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impulse Control Disorders, Parkinson's Disease

Keywords

Parkinson's disease, Impulse control disorders, Diffusion tensor imaging, MRI, Mesocorticolimbic pathway

Brief summary

Impulse control disorders (ICD) are frequent in Parkinson's Disease. Neurobiological substrates of these symptoms are largely unknown. The investigators aim to explore mesocorticolimbic pathway in Parkinson's disease patients with impulse control disorders (ICD) using an MRI technique called tensor diffusion imaging (DTI). More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD. Secondary objectives are to demonstrate a difference in volume of VTA, in FA in others structures included in reward system (prefrontal cortex, nucleus accumbens, amygdala), and in number of fibers between VTA and the other structures of reward system between this two groups. Other objective is to measure and compare these same variables between Parkinson's patients and healthy controls. We hypothesized that a denervation of mesocorticolimbic pathway predisposes Parkinson's patients to ICD.

Detailed description

Type of study: Prospective, case control study. Number of centers: 1 (Clermont-Ferrand) Patients : Inclusion of 25 patients with Parkinson's disease and impulse control disorders (inclusion's criteria detailed later), 25 matched Parkinson's disease patients without impulse control disorders and 25 healthy volunteers. Study Performance : J0 (inclusion; 3 hours) : Each subject will perform a clinical and neurological examination (UPDRS) and a neuropsychological evaluation for diagnostic and quantification of impulse control disorders and to ensure of the absence of exclusion criteria. J0+1week (MRI; 1hour) Each subject will then have an MRI acquisition including anatomical sequences (T1 and T2 weighted sequences) and a diffusion tensor imaging sequence (60 directions). Analysis Analysis (Pre-processing and processing) will be realized with the Oxford Centre for Functional MRI of the Brain (FMRIB) Software (FSL).

Interventions

DEVICEMRI

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Parkinson's disease (UK Parkinson's Disease Society Brain Bank Criteria) * from 18 to 85 years old * Impulse control disorder (one item ICD ≥2 at the scale ECMP : Evaluation Comportementale de la maladie de Parkinson)

Exclusion criteria

* Dementia (Mini Mental State \< 26 or MATTIS \< 130) * Apathy (LARS (Lille Apathy Rating Scale) \> 7) * Depression (MADRS (Montgomery and Alsberg Depression Scale) ≥16 * Contra indication to MRI (claustrophobia, deep brain stimulation, pace maker…)

Design outcomes

Primary

MeasureTime frame
Fractional anisotropy (data of diffusion tensor imaging, a technique of MRI)1 day

Secondary

MeasureTime frame
Fractional anisotropy in préfrontal cortex1 day
Volume of ventral tegmental area1 day
Number of fibers between ventral tegmental area and other structures of the reward system1 day

Countries

France

Contacts

Primary ContactPatrick LACARIN
placarin@chu-clermontferrand.fr04 73 75 10 81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026